Developing new economic models to incentivise antibiotic discovery and development activities while safeguarding the efficacy of antibiotics by researching and advocating their appropriate use.
Revitalizing the Antibiotic Pipeline: DRIVE-AB Conference Speakers Announced
The speakers and panelists for the upcoming DRIVE-AB conference, Revitalizing the Antibiotic Pipeline, have now beenUN Interagency Coordination Group on AMR Opens Online Consultation On Draft Work Plan
The UN Secretary-General’s Interagency Coordination Group on Antimicrobial Resistance (IACG), whose establishment...Economic Incentives for Antimicrobial Drugs Proposed by Duke-Margolis Centre
The Duke-Margolis Centre for Health Policy in the United States has released a paper describing U.S. policy approaches that...DRIVE-AB Steering Committee Publishes Advice to G20 Leaders in The Lancet Infectious Diseases
In anticipation of the 2017 G20 Summit in Hamburg, Germany, on 7-8 July, the...Statement on ReAct’s Departure from the DRIVE-AB Consortium
DRIVE-AB regrets that ReAct has decided to leave the DRIVE-AB partnership. We believe that ReAct has contributed positively...